{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:13:42Z","timestamp":1786986822576,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015686","name":"The Christie NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clbc.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T19:50:45Z","timestamp":1733514645000},"page":"368-379.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1828-1867","authenticated-orcid":false,"given":"Nicole L.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-3741","authenticated-orcid":false,"given":"Ann","family":"Tivey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siow Chin","family":"Phua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Raby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Hulmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha J.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.clbc.2024.12.001_bib0001","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.001_bib0002","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with Ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clbc.2024.12.001_bib0003","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.001_bib0004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clbc.2024.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.001_bib0006","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.clbc.2024.12.001_bib0007","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2024.12.001_bib0008","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.001_bib0009","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.clbc.2024.12.001_bib0010","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clbc.2024.12.001_bib0011","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib Plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.clbc.2024.12.001_bib0013","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.001_bib0014","unstructured":"National Institute for Health and Care Excellence (NICE). Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. 2022 [Accessed November 4, 2023]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta810."},{"issue":"9","key":"10.1016\/j.clbc.2024.12.001_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clbc.2024.12.001_bib0016","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.001_bib0017","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11912-023-01393-6","article-title":"Advances in endocrine therapy for hormone receptor-positive advanced breast cancer","volume":"25","author":"Ziyeh","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/cancers15010051","article-title":"Systemic therapy for HER2-positive metastatic breast cancer: current and future trends","volume":"15","author":"Vega Cano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2024.12.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2024.12.001_bib0020","unstructured":"House of Commons Health and Social Care Committee. Cancer services twelfth report of session 2021\u201322. 2022 [Accessed March 1, 2024]. Available from: https:\/\/committees.parliament.uk\/publications\/9562\/documents\/161967\/default\/."},{"key":"10.1016\/j.clbc.2024.12.001_bib0021","unstructured":"Royal College of Radiologists (RCR). Clinical oncology workforce census. 2022 [Accessed March 8, 2024]. Available from: https:\/\/www.rcr.ac.uk\/news-policy\/policy-reports-initiatives\/clinical-oncology-census-reports\/."},{"issue":"2","key":"10.1016\/j.clbc.2024.12.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55388","article-title":"Financial toxicity among patients with breast cancer worldwide: a systematic review and meta-analysis","volume":"6","author":"Ehsan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"15_suppl","key":"10.1016\/j.clbc.2024.12.001_bib0023","doi-asserted-by":"crossref","first-page":"e19580","DOI":"10.1200\/jco.2010.28.15_suppl.e19580","article-title":"Financial and psychosocial impacts of adjuvant chemotherapy in older colorectal cancer patients","volume":"28","author":"Elkin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.001_bib0024","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5152\/tjbh.2016.3041","article-title":"Psychiatric symptoms and psychosocial problems in patients with breast cancer","volume":"12","author":"\u0130zci","year":"2016","journal-title":"J Breast Health"},{"issue":"12","key":"10.1016\/j.clbc.2024.12.001_bib0025","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.clon.2021.06.004","article-title":"The routine clinical implementation of electronic patient-reported outcome measures (ePROMs) at The Christie NHS Foundation Trust","volume":"33","author":"Crockett","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41687-023-00544-4","article-title":"Patient and clinician-reported experiences of using electronic patient reported outcome measures (ePROMs) as part of routine cancer care","volume":"7","author":"Payne","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.001_bib0027","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7812\/TPP\/23.046","article-title":"Real-world use of electronic patient-reported outcome (ePRO) tools integrated in the electronic medical record during radiation therapy for head and neck cancer: feasibility study","volume":"27","author":"Katzel","year":"2023","journal-title":"Perm J"},{"key":"10.1016\/j.clbc.2024.12.001_bib0028","doi-asserted-by":"crossref","first-page":"n1647","DOI":"10.1136\/bmj.n1647","article-title":"Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART)","volume":"374","author":"Maguire","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.001_bib0029","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2013.48.6662","article-title":"Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trial","volume":"32","author":"Berry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.001_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clbc.2024.12.001_bib0031","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clbc.2024.12.001_bib0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.clbc.2024.12.001_bib0033","doi-asserted-by":"crossref","first-page":"djx029","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients","volume":"109","author":"Denis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.001_bib0034","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2024.12.001_bib0035","article-title":"Experience with the routine use of electronic patient-reported outcome measures for patients with lung cancer","volume":"7","author":"Crockett","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.clbc.2024.12.001_bib0036","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11764-020-00942-3","article-title":"ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows","volume":"15","author":"Riis","year":"2021","journal-title":"J Cancer Surviv"},{"issue":"3","key":"10.1016\/j.clbc.2024.12.001_bib0037","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11136-015-1207-0","article-title":"AmbuFlex: tele-patient-reported outcomes (telePRO) as the basis for follow-up in chronic and malignant diseases","volume":"25","author":"Schougaard","year":"2016","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.001_bib0038","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.001_bib0039","unstructured":"U.S. Department Of Health And Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017 [Accessed December 21, 2024]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.clbc.2024.12.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1328871","article-title":"A study demonstrating users\u2019 preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE\u00ae in patients with lung cancer","volume":"14","author":"Jordan","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0041","article-title":"Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy","volume":"3","author":"Liao","year":"2024","journal-title":"BMJ Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.12.001_bib0042","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40273-018-0623-8","article-title":"Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries","volume":"36","author":"Janssen","year":"2018","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0043","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bjps.2018.08.023","article-title":"The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction","volume":"72","author":"Kouwenberg","year":"2019","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"5_Supplement","key":"10.1016\/j.clbc.2024.12.001_bib0044","doi-asserted-by":"crossref","first-page":"P6-05-43","DOI":"10.1158\/1538-7445.SABCS22-P6-05-43","article-title":"Abstract P6-05-43: validity of EQ-5D-5L for women with breast cancer","volume":"83","author":"Torres","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.001_bib0045","article-title":"Experience with the routine use of electronic patient-reported outcome measures for patients with lung cancer","volume":"7","author":"Crockett","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"10.1016\/j.clbc.2024.12.001_bib0046","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/OP.23.00038","article-title":"Feasibility of symptom monitoring during the first year of endocrine therapy for early breast cancer using patient-reported outcomes collected via smartphone app","volume":"19","author":"Smith","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clbc.2024.12.001_bib0047","article-title":"A pilot project investigating the use of ONCOpatient\u00ae\u2014an electronic patient-reported outcomes app for oncology patients","volume":"9","author":"Macanovic","year":"2023","journal-title":"Digit Health"},{"issue":"7","key":"10.1016\/j.clbc.2024.12.001_bib0048","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1200\/JCO.20.02015","article-title":"Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy","volume":"39","author":"Absolom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2024.12.001_bib0049","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/OP.23.00415","article-title":"Lessons learned and practice pearls: optimal integration of electronic patient-reported outcomes in the medical oncology clinic","volume":"19","author":"O'Sullivan","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.clbc.2024.12.001_bib0051","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1371\/journal.pctr.0010009","article-title":"Factors that can affect the external validity of randomised controlled trials","volume":"1","author":"Rothwell","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.clbc.2024.12.001_bib0052","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.annonc.2023.09.471","article-title":"274P impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): analyses from the monarchE study","volume":"34","author":"O'Shaughnessy","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:24Z","timestamp":1762548984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1526820924003409"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}